Dr. Devon L. Evans, MD
Hematology & Oncology (Hematology & Oncology Physician)
11 Rock Row Ste 120
Westbrook, ME 04092
Who else practices at this address →
Cumberland County includes primary care (5% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 645
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Jefferson Medical College of Thomas Jefferson University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
ME license 017411 · NH license 13583
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mainehealth Maine Medical Center Portland, ME
- Portsmouth Regional Hospital Portsmouth, NH
- Northern Light Mercy Hospital Portland, ME
- York Hospital York, ME
- Memorial Hospital, the North Conway, NH
Medical groups
- Maine Center for Cancer Medicine and Blood Disorders PA (70 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 645
- Services billed
- 210,396
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 45,750 | 41 |
| Injection, pembrolizumab, 1 mg | 18,000 | 21 |
| Injection, denosumab, 1 mg | 11,400 | 69 |
| Injection, paclitaxel, 1 mg | 8,825 | 11 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2,790 | 16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,555 | 75 |
| Injection, atropine sulfate, 0.01 mg | 1,920 | 11 |
| Injection, granisetron hydrochloride, 100 mcg | 1,341 | 40 |
| Established patient office or other outpatient visit, 30-39 minutes | 981 | 293 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 744 | 217 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxyurea Other prescribers in Westbrook, ME | 82 |
| Anastrozole Other prescribers in Westbrook, ME | 70 |
| Prednisone Other prescribers in Westbrook, ME | 64 |
| Revlimid (lenalidomide) | 51 |
| Levothyroxine Sodium Other prescribers in Westbrook, ME | 48 |
| Gabapentin Other prescribers in Westbrook, ME | 43 |
| Darzalex Faspro (daratumumab-hyaluronidase-fihj) | 43 |
| Erleada (apalutamide) | 42 |
| Ondansetron Odt (ondansetron) Other prescribers in Westbrook, ME | 37 |
| Imatinib Mesylate | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 36 payments worth $861 in total to this clinician.
| AbbVie Inc. | $143 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $131 |
| Daiichi Sankyo Inc. | $86.33 |
| Janssen Biotech, Inc. | $84.76 |
| Asd Specialty Healthcare, LLC | $56.42 |
| E.r. Squibb & Sons, L.l.c. | $47.69 |
| Novocure Inc. | $40.55 |
| Merck Sharp & Dohme LLC | $37.17 |
| Food and Beverage | $861 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $6,307 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. · Terminated · NCT03906071
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.